Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Catalyst Biosciences, Inc is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 34 staff and has a trailing 12-month revenue of around USD$18.9 million.
|Latest market close||USD$5.77|
|52-week range||USD$3.43 - USD$8.66|
|50-day moving average||USD$6.1321|
|200-day moving average||USD$5.6208|
|Wall St. target price||USD$20.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.961|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-7.09%|
|1 month (2020-12-17)||-16.50%|
|3 months (2020-10-16)||-9.98%|
|6 months (2020-07-16)||0.17%|
|1 year (2020-01-16)||-21.17%|
|2 years (2019-01-16)||-29.81%|
|3 years (2018-01-16)||14.18|
|5 years (2016-01-15)||157.59%|
Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$18.9 million|
|Gross profit TTM||USD$-43,859,000|
|Return on assets TTM||-31.75%|
|Return on equity TTM||-58.11%|
|Market capitalisation||USD$143 million|
TTM: trailing 12 months
There are currently 912,042 Catalyst Biosciences shares held short by investors – that's known as Catalyst Biosciences's "short interest". This figure is 6.6% down from 976,001 last month.
There are a few different ways that this level of interest in shorting Catalyst Biosciences shares can be evaluated.
Catalyst Biosciences's "short interest ratio" (SIR) is the quantity of Catalyst Biosciences shares currently shorted divided by the average quantity of Catalyst Biosciences shares traded daily (recently around 323419.14893617). Catalyst Biosciences's SIR currently stands at 2.82. In other words for every 100,000 Catalyst Biosciences shares traded daily on the market, roughly 2820 shares are currently held short.
However Catalyst Biosciences's short interest can also be evaluated against the total number of Catalyst Biosciences shares, or, against the total number of tradable Catalyst Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalyst Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Catalyst Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0327% of the tradable shares (for every 100,000 tradable Catalyst Biosciences shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalyst Biosciences.
Find out more about how you can short Catalyst Biosciences stock.
We're not expecting Catalyst Biosciences to pay a dividend over the next 12 months.
Catalyst Biosciences's shares were split on a 1:15 basis on 13 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.
Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $3.43 up to $8.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 2.0577. This would suggest that Catalyst Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.